We were thrilled to attend the World Evidence, Pricing and Access Congress (World EPA) in Amsterdam ...
Read moreCharlie Hewitt from Remap Consulting initiated today’s session by providing a description of the c...
Read moreAUTHORS: Joyce Atim, Rahul Vadehra Rare diseases have a significant impact on people worldwide...
Read moreEU HTA Regulation goes live: A new era for HTA begins The much-awaited implementation of the r...
Read moreOur review of the 2024 pricing and market access revealed key challenges facing the pharmaceutical i...
Read moreThere is no excerpt because this is a protected post.
Read moreAUTHORS: Amy Boyers, Solen Monteil, Mariam Bibi OBJECTIVES Early Access Programmes (EAPs) prov...
Read moreThe European Commission's 4th implementing act outlines how health tech developers can obtain early ...
Read moreWe examine how real-world evidence strategies help address uncertainties in rare disease treatments ...
Read moreAchieving HTA approval for orphan drugs requires strategic planning, early engagement, strong eviden...
Read more